Literature DB >> 10639692

Acute effect of glucose tablets on desire to smoke.

R West1, S Courts, S Beharry, S May, P Hajek.   

Abstract

RATIONALE: Previous research suggests that glucose may reduce desire to smoke during periods of abstinence but a definitive test is needed.
OBJECTIVE: The present study aimed to determine whether a single administration of oral glucose would reduce desire to smoke in abstaining smokers.
METHODS: Thirty-eight smokers attended the laboratory in the afternoon having not smoked since the previous evening. They rated their desire to smoke immediately before and at 5-min intervals for 20 min after chewing four 3-g glucose tablets (experimental group) or four matched placebo tablets (control group).
RESULTS: Ratings of desire to smoke decreased to a greater extent in the experimental than the control group. The effect was apparent after 10 min. There was no difference between the groups in terms of feeling "sick" or "satisfied".
CONCLUSION: A single dose of glucose has a relatively rapid and detectable effect on desire to smoke and the effect is not mediated by feeling sick. Glucose tablets may be useful in helping to control desire to smoke during periods of abstinence.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10639692     DOI: 10.1007/s002130051174

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  12 in total

Review 1.  Current approaches to the management of smoking cessation.

Authors:  Gay Sutherland
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Is the ten-item Questionnaire of Smoking Urges (QSU-brief) more sensitive to abstinence than shorter craving measures?

Authors:  Robert West; Michael Ussher
Journal:  Psychopharmacology (Berl)       Date:  2009-12-22       Impact factor: 4.530

3.  Blood glucose levels produced by glucose tablets in abstaining smokers.

Authors:  Jonathan Foulds; Jyoti D Parth; Michelle T Bover-Manderski
Journal:  Psychopharmacology (Berl)       Date:  2010-03-02       Impact factor: 4.530

Review 4.  Glucose for smoking cessation: does it have a role?

Authors:  R West
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

5.  Low-dose naltrexone augmentation of nicotine replacement for smoking cessation with reduced weight gain: a randomized trial.

Authors:  Benjamin A Toll; Marney White; Ran Wu; Boris Meandzija; Peter Jatlow; Robert Makuch; Stephanie S O'Malley
Journal:  Drug Alcohol Depend       Date:  2010-06-12       Impact factor: 4.492

6.  Lack of attentional retraining effects in cigarette smokers attempting cessation: a proof of concept double-blind randomised controlled trial.

Authors:  Rachna Begh; Marcus R Munafò; Saul Shiffman; Stuart G Ferguson; Linda Nichols; Mohammed A Mohammed; Roger L Holder; Stephen Sutton; Paul Aveyard
Journal:  Drug Alcohol Depend       Date:  2015-02-09       Impact factor: 4.492

7.  A randomised placebo-controlled trial of oral hydrocortisone for treating tobacco withdrawal symptoms.

Authors:  Michael Ussher; Paul Aveyard; Fiona Reid; Robert West; Phil Evans; Angela Clow; Frank Hucklebridge; Julie Fuller; Judith Ibison; Andrew Steptoe
Journal:  Psychopharmacology (Berl)       Date:  2011-02-09       Impact factor: 4.530

8.  Impulsivity as a behavioral measure of withdrawal of orally delivered PCP and nondrug rewards in male and female monkeys.

Authors:  Marilyn E Carroll; Jami L Mach; Rachel M La Nasa; Jennifer L Newman
Journal:  Psychopharmacology (Berl)       Date:  2009-08-21       Impact factor: 4.530

9.  Effect of glucose on tobacco craving. Is it mediated by tryptophan and serotonin?

Authors:  Ivan Berlin; Florence Vorspan; Dominique Warot; Benjamin Manéglier; Odile Spreux-Varoquaux
Journal:  Psychopharmacology (Berl)       Date:  2004-07-31       Impact factor: 4.530

10.  A randomised trial of glucose tablets to aid smoking cessation.

Authors:  Robert West; Sylvia May; Andy McEwen; Hayden McRobbie; Peter Hajek; Eleni Vangeli
Journal:  Psychopharmacology (Berl)       Date:  2009-10-27       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.